Down Syndrome Risk and HCG Levels by Week

In pregnancies affected by Down syndrome (trisomy 21), levels of human chorionic gonadotropin tend to be higher than in unaffected pregnancies, and this elevation is one of the key biochemical signals that prenatal screening programs rely on. The relationship between hCG and Down syndrome risk is not a simple threshold, though. How much hCG rises, which form of hCG is measured, and when during pregnancy the blood is drawn all shape what the result means for any individual pregnancy.

What Happens to HCG in a Down Syndrome Pregnancy

In a typical pregnancy, hCG rises rapidly during the first trimester, peaks somewhere around weeks 9 to 12, and then gradually declines through the second trimester. In pregnancies where the fetus has trisomy 21, hCG follows the same general curve but at a higher level. By the second trimester, the median hCG in Down syndrome pregnancies runs roughly twice the normal median. This pattern holds whether the lab measures total hCG or just the free beta subunit, though the free beta subunit tends to be more discriminating as a screening tool.

The biological reason for this elevation traces back to the placenta. Research on trisomy 21 placentas has found that the tissue responsible for producing hCG, the syncytiotrophoblast, actually forms abnormally. Cells from these placentas show reduced synthesis and secretion of hCG compared to cells from chromosomally normal placentas, along with lower transcript levels of both the alpha and beta subunits of the hormone.¹ That sounds like it should produce less hCG, not more, and that paradox points to what is really going on in the mother’s bloodstream.

A separate study found that while the placenta in Down syndrome pregnancies does produce more hCG beta mRNA (which correlates with the high serum levels), the mature receptor that normally binds and clears circulating hCG is significantly reduced. In other words, the hormone accumulates in the mother’s blood partly because the placenta cannot use it efficiently.² So the elevated hCG is a consequence of placental dysfunction, not a sign that the placenta is working harder than normal.

First Trimester Screening and Free Beta-hCG

The most widely used early screening approach combines three measurements taken between about 11 and 13 weeks of pregnancy: an ultrasound measurement of the fluid at the back of the fetal neck (nuchal translucency), a blood level of free beta-hCG, and a blood level of pregnancy-associated plasma protein A (PAPP-A). In trisomy 21, free beta-hCG tends to be elevated while PAPP-A tends to be low.³ Nuchal translucency is often increased as well. The combination of all three gives far better results than any single measurement alone.

How much better? Modeling based on the age distribution of births suggests that combining biochemistry with nuchal translucency detects about 87% of Down syndrome cases at a 5% false-positive rate. Biochemistry by itself catches around 61%, and nuchal translucency alone about 73%.⁴ A large analysis of nearly 15,000 pregnancies confirmed this hierarchy: nuchal translucency had the strongest individual performance, followed by PAPP-A, with free beta-hCG contributing the least on its own but still improving overall accuracy when added to the panel.⁵

A Cochrane review pooling over 200,000 pregnancies found that the double marker combination of PAPP-A and free beta-hCG with maternal age detected about seven out of every ten Down syndrome pregnancies at a 5% false-positive rate, confirming that these blood markers perform significantly better together than individually.⁶ The key takeaway is that hCG is a useful piece of the puzzle but not a standalone diagnostic tool. An elevated free beta-hCG by itself is common in perfectly healthy pregnancies.

Second Trimester Screening and Total HCG

If screening is done later, between about 15 and 20 weeks, the standard approach is the “quad screen,” which measures four markers in the mother’s blood: alpha-fetoprotein (AFP), total hCG (or free beta-hCG), unconjugated estriol, and inhibin A.⁷ In a Down syndrome pregnancy during the second trimester, hCG is elevated while AFP and unconjugated estriol tend to be low. Inhibin A is typically elevated as well.

A Cochrane review covering over 340,000 pregnancies found that double and triple test combinations using AFP, unconjugated estriol, and total or free beta-hCG detect six to seven out of every ten Down syndrome pregnancies at a 5% false-positive rate.⁸ Adding inhibin A as a fourth marker improves this somewhat. Statistical models using meta-analysis data predict that a three-marker combination yields about a 67% detection rate at that same 5% false-positive threshold.⁹

The evolution of screening performance over the decades is worth noting. Detection rates have climbed from about 30% when maternal age was the only criterion, to 60–75% with second-trimester blood markers, to roughly 90% with the first-trimester combined test of nuchal translucency plus biochemistry.¹⁰ This progression explains why first-trimester combined screening is generally preferred when timing allows.

How the Numbers Are Reported and Adjusted

Raw hCG levels in international units per liter vary enormously from one week of pregnancy to the next and from one lab to another. To make screening work, labs convert each woman’s raw result into a “multiple of the median,” or MoM. A MoM of 1.0 means your level sits right at the median for your gestational age. In Down syndrome pregnancies, free beta-hCG typically comes back around 2.0 MoM, meaning twice the expected median, though individual cases scatter widely around that central tendency.

This conversion step is more complex than it sounds. The median value that serves as the denominator needs to be calibrated for the specific population the lab serves, not borrowed from a textbook. Research on large datasets has shown that using locally derived medians (sometimes called “indigenized” medians) produces more accurate risk estimates than relying on the software’s built-in defaults.¹¹ When adjustments are poorly calibrated, both false-positive and false-negative rates can drift in ways that affect thousands of pregnancies.

Factors That Shift HCG Levels Without Indicating Down Syndrome

A high hCG reading does not automatically mean elevated Down syndrome risk. Several maternal and pregnancy characteristics push hCG levels up or down independently of fetal chromosomes. A large population-based study, the Generation R cohort, found that maternal smoking, body mass index, parity, ethnicity, fetal sex, placental weight, and symptoms of hyperemesis gravidarum all independently influenced total hCG levels.¹² The screening software attempts to account for these variables through correction factors built into the MoM calculation.

A 2023 review confirmed that significant differences in marker concentrations exist among pregnant individuals of different racial backgrounds, between smokers and non-smokers, and between those with insulin-dependent diabetes and those without.¹³ If these factors are not correctly entered into the screening algorithm, the resulting risk estimate can be misleading. For example, a woman with a higher BMI tends to have lower hCG concentrations simply due to dilution in a larger blood volume. Without the weight adjustment, her MoM could look falsely reassuring.

Vanishing Twins and Multiple Pregnancies

One scenario that can dramatically distort hCG-based screening results involves pregnancies that started as twins but where one embryo stopped developing early on, sometimes called a “vanishing twin.” The remnant pregnancy tissue can continue to produce hormones for weeks, pushing PAPP-A and free beta-hCG higher than expected for a singleton pregnancy.¹⁴ This is especially relevant for pregnancies conceived through assisted reproduction, where the rate of multiple implantation and subsequent early loss is higher.

Research has found that when the loss of the second embryo is first discovered at the time of the nuchal translucency scan, the reliability of the serum risk assessment becomes questionable compared to straightforward singleton pregnancies.¹⁵ If you know a vanishing twin was involved, your provider may recommend skipping biochemical screening and going directly to other testing options.

How Down Syndrome Differs from Other Trisomies

The hCG pattern in Down syndrome is distinctly different from the patterns seen in trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome). In trisomy 21, free beta-hCG is elevated. In trisomies 18 and 13, free beta-hCG is reduced. All three conditions share increased nuchal translucency and decreased PAPP-A in the first trimester.³ In the second trimester, trisomy 18 pregnancies show reduced AFP, unconjugated estriol, and free beta-hCG, making the biochemical profile almost the opposite of trisomy 21.¹⁶

This distinction matters for interpretation. If your screening returns low hCG alongside low PAPP-A and increased nuchal translucency, the concern shifts away from Down syndrome and toward trisomy 18 or 13. Modern screening software calculates separate risk estimates for each condition using the same set of blood draws and ultrasound measurements.

Hyperglycosylated HCG as a Stronger Signal

Not all hCG molecules are identical. A variant called hyperglycosylated hCG (sometimes labeled H-hCG or “invasive trophoblast antigen”) carries extra sugar molecules and appears to be produced primarily by immature trophoblast cells. In Down syndrome pregnancies, this particular variant is disproportionately elevated compared to regular hCG. One study found that the median hyperglycosylated hCG was 9.5 times higher in Down syndrome cases than the normal median, compared to the roughly twofold elevation seen with standard hCG assays. Used as a single marker, it detected 80% of Down syndrome cases at a 5% false-positive rate.¹⁷

An earlier investigation reported that H-hCG identified 90% of Down syndrome cases at a 5% false-positive rate, more than twice the detection achieved by a standard hCG assay in the same samples.¹⁸ In the second trimester, hyperglycosylated hCG still outperformed total hCG and free beta-hCG on a marker-for-marker basis, with a median above 3.0 MoM in affected pregnancies, though when substituted into the standard multi-marker panel it performed comparably rather than dramatically better.¹⁹ Despite these promising numbers, hyperglycosylated hCG has not replaced standard hCG in routine screening, partly because widespread commercial assays for it are not as readily available and partly because cell-free DNA screening has overtaken biochemical-only approaches for high-risk populations.

Cell-Free DNA Screening and Where HCG Still Fits

Non-invasive prenatal testing, which analyzes fragments of fetal DNA circulating in the mother’s blood, has significantly changed the screening landscape. For Down syndrome specifically, NIPT sensitivity approaches 100% with a specificity above 99%, far surpassing the performance of any combination of hCG and other biochemical markers. One study directly comparing the two approaches in the same population found NIPT sensitivity of 100% versus about 77% for traditional serum screening.²⁰

One increasingly popular strategy uses traditional first-trimester biochemistry and nuchal translucency as an initial screen, then sends only the higher-risk results on to NIPT as a secondary step. Modeling suggests this reflexive approach loses only about 1% in detection while dropping the false-positive rate to around 0.2%, which dramatically reduces unnecessary invasive procedures like amniocentesis.²¹

Does this mean hCG-based screening is obsolete? Not yet, and perhaps not ever for certain purposes. A review of the tradeoffs pointed out that replacing first-trimester combined screening entirely with NIPT would mean losing other valuable information that the traditional approach provides: accurate pregnancy dating, early detection of major structural abnormalities, identification of multiple pregnancies, and the opportunity to screen for early preeclampsia.²² In many healthcare systems, the combined approach remains the standard first step, with NIPT offered as an add-on for those who screen positive or who prefer it upfront.

Cost and Access Across Different Healthcare Systems

The choice between screening strategies is not purely a medical decision. NIPT costs substantially more than a blood draw for hCG and PAPP-A, which matters in resource-limited settings. An analysis modeling different strategies for developing countries found that incorporating NIPT was the most cost-beneficial option only when the price per test fell below a certain threshold (roughly $400 or less in the modeled scenario). When NIPT was too expensive, the most cost-beneficial approach was the traditional combined first-trimester screen followed by second-trimester serum testing.²³ This means that for much of the world, hCG-based biochemical screening is not a second-best alternative but the primary realistic option.

When High HCG Means Something Else Entirely

An elevated hCG result during screening can understandably cause anxiety about chromosomal conditions, but the vast majority of pregnancies with high hCG are chromosomally normal. At the same time, significantly elevated hCG in the second trimester has been linked to other pregnancy complications. A systematic review and meta-analysis found that hCG levels at or above 2.0 to 2.5 MoM were associated with roughly double the risk of preeclampsia and a modest increase in preterm delivery risk, though the authors cautioned that confidence in the evidence was low.²⁴

A prospective cohort study from the Generation R population reported that high hCG concentrations were associated with a 1.5 to 2.7-fold increased risk of preeclampsia, depending on the cutoff used, and that elevated hCG tracked with an imbalance in angiogenic factors during early pregnancy.²⁵ An earlier smaller study reported an even stronger association, with an odds ratio near 6 for preeclampsia among women with elevated second-trimester hCG.²⁶

These associations do not mean that high hCG causes preeclampsia or that every woman with elevated hCG will develop it. The overlap likely reflects shared placental dysfunction: the same problems that lead to excessive hCG in the bloodstream may also contribute to the poor placental vascular development that underlies preeclampsia. Some providers use unexplained elevations in second-trimester hCG as a prompt for closer blood-pressure monitoring later in pregnancy, though there is no consensus guideline mandating this.

Why Your Raw HCG Number Cannot Tell You a Risk by Itself

One of the most common misconceptions is that you can look up your hCG level on a week-by-week chart and determine whether it falls in a “Down syndrome range.” This does not work, for several reasons. First, the range of normal hCG at any given gestational week is enormous. At 10 weeks, values from roughly 25,000 to over 200,000 mIU/mL can all be normal. Second, the screening algorithms do not use the raw number; they use the MoM after adjusting for gestational age, weight, ethnicity, smoking status, mode of conception, and sometimes other factors. Third, hCG is only one input in a multi-marker calculation that also includes PAPP-A (or AFP and estriol in the second trimester) and, in the first trimester, the nuchal translucency measurement. The final risk figure that appears on your screening report is the output of a statistical model that weighs all of these inputs against your age-related baseline risk.

So if you see a high hCG value on a lab printout, resist the urge to Google “high hCG and Down syndrome” and panic. The number means very little without the rest of the calculation, and even a “screen positive” result on the full combined test indicates only elevated risk, not a diagnosis. Most screen-positive pregnancies turn out to be chromosomally normal after follow-up testing.